Logo for PHAXIAM Therapeutics SA

PHAXIAM Therapeutics Investor Relations Material

Latest events

Logo for PHAXIAM Therapeutics SA

Q2 2024

PHAXIAM Therapeutics
Logo for PHAXIAM Therapeutics

Q2 2024

26 Sep, 2024
Logo for PHAXIAM Therapeutics

Q1 2024

15 May, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from PHAXIAM Therapeutics SA

Access all reports
PHAXIAM Therapeutics S.A. is a biopharmaceutical company focused on developing innovative treatments for drug-resistant bacterial infections. Leveraging phages, which are viruses that specifically target and kill bacteria, the company is developing a portfolio aimed at combating some of the most challenging and resistant bacterial strains, including Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. PHAXIAM is also involved in advancing clinical-stage therapies, including eryaspase, which is being tested in late-stage clinical trials for conditions such as pancreatic cancer and acute lymphoblastic leukemia. The company is headquartered in Lyon, France, and its shares are listed on the Euronext Paris.